RAPT Therapeutics, Inc. Research and Development Expense
RAPT Therapeutics, Inc. reported Research and Development Expense of $12.03 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-11-06
- RAPT Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $12.03M, a 9.79% decline year-over-year.
- RAPT Therapeutics, Inc. research and development expense for the quarter ending 2025-06-30 was $12.34M, a 45.49% decline year-over-year.
- RAPT Therapeutics, Inc. research and development expense for the quarter ending 2025-03-31 was $12.04M, a 51.41% decline year-over-year.
- RAPT Therapeutics, Inc. research and development expense for the quarter ending 2024-12-31 was $46.46M, a 73.58% increase year-over-year.
- RAPT Therapeutics, Inc. research and development expense for fiscal 2024 was $107.22M, a 6.15% increase from fiscal 2023.
- RAPT Therapeutics, Inc. research and development expense for fiscal 2023 was $101.00M, a 50.56% increase from fiscal 2022.
- RAPT Therapeutics, Inc. research and development expense for fiscal 2022 was $67.08M, a 17.72% increase from fiscal 2021.
- RAPT Therapeutics, Inc. research and development expense for fiscal 2021 was $56.98M, a 25.28% increase from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $12.03M 10-Q · filed 2025-11-06 | $24.37M derived: sum of 2 quarters · filed 2025-11-06 | $36.42M 10-Q · filed 2025-11-06 | $82.87M derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | $12.34M 10-Q · filed 2025-08-07 | $24.38M 10-Q · filed 2025-08-07 | $70.84M derived: sum of 3 quarters · filed 2025-08-07 | $84.18M derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-03-31 | $12.04M 10-Q · filed 2025-05-08 | $58.50M derived: sum of 2 quarters · filed 2025-05-08 | $71.84M derived: sum of 3 quarters · filed 2025-11-06 | $94.48M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-12-31 | $46.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $59.80M derived: sum of 2 quarters · filed 2025-11-06 | $82.44M derived: sum of 3 quarters · filed 2025-11-06 | $107.22M 10-K · filed 2025-03-06 |
| 2024-09-30 | $13.34M 10-Q · filed 2025-11-06 | $35.98M derived: sum of 2 quarters · filed 2025-11-06 | $60.76M 10-Q · filed 2025-11-06 | $87.53M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $22.64M 10-Q · filed 2025-08-07 | $47.42M 10-Q · filed 2025-08-07 | $74.19M derived: sum of 3 quarters · filed 2025-08-07 | $101.21M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $24.78M 10-Q · filed 2025-05-08 | $51.55M derived: sum of 2 quarters · filed 2025-05-08 | $78.57M derived: sum of 3 quarters · filed 2025-05-08 | $100.21M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $26.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $53.79M derived: sum of 2 quarters · filed 2025-03-06 | $75.43M derived: sum of 3 quarters · filed 2025-03-06 | $101.00M 10-K · filed 2025-03-06 |
| 2023-09-30 | $27.02M 10-Q · filed 2024-11-12 | $48.66M derived: sum of 2 quarters · filed 2024-11-12 | $74.24M 10-Q · filed 2024-11-12 | $93.69M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $21.64M 10-Q · filed 2024-08-08 | $47.22M 10-Q · filed 2024-08-08 | $66.67M derived: sum of 3 quarters · filed 2024-08-08 | $83.27M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $25.57M 10-Q · filed 2024-05-09 | $45.03M derived: sum of 2 quarters · filed 2024-05-09 | $61.63M derived: sum of 3 quarters · filed 2024-05-09 | $75.99M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $19.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $36.05M derived: sum of 2 quarters · filed 2024-03-07 | $50.41M derived: sum of 3 quarters · filed 2024-03-07 | $67.08M 10-K · filed 2024-03-07 |
| 2022-09-30 | $16.60M 10-Q · filed 2023-11-13 | $30.96M derived: sum of 2 quarters · filed 2023-11-13 | $47.63M 10-Q · filed 2023-11-13 | $61.93M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $14.36M 10-Q · filed 2023-08-11 | $31.03M 10-Q · filed 2023-08-11 | $45.33M derived: sum of 3 quarters · filed 2023-08-11 | $61.05M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $16.67M 10-Q · filed 2023-05-11 | $30.97M derived: sum of 2 quarters · filed 2023-05-11 | $46.69M derived: sum of 3 quarters · filed 2023-05-11 | $59.88M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $14.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $30.02M derived: sum of 2 quarters · filed 2023-03-14 | $43.21M derived: sum of 3 quarters · filed 2023-03-14 | $56.98M 10-K · filed 2023-03-14 |
| 2021-09-30 | $15.72M 10-Q · filed 2022-11-10 | $28.91M derived: sum of 2 quarters · filed 2022-11-10 | $42.69M 10-Q · filed 2022-11-10 | $53.59M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $13.19M 10-Q · filed 2022-08-11 | $26.96M 10-Q · filed 2022-08-11 | $37.87M derived: sum of 3 quarters · filed 2022-08-11 | $50.78M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $13.77M 10-Q · filed 2022-05-11 | $24.68M derived: sum of 2 quarters · filed 2022-05-11 | $37.59M derived: sum of 3 quarters · filed 2022-05-11 | $48.57M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $10.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $23.82M derived: sum of 2 quarters · filed 2022-03-10 | $34.80M derived: sum of 3 quarters · filed 2022-03-10 | $45.48M 10-K · filed 2022-03-10 |
| 2020-09-30 | $12.91M 10-Q · filed 2021-11-10 | $23.90M derived: sum of 2 quarters · filed 2021-11-10 | $34.58M 10-Q · filed 2021-11-10 | $44.77M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $10.99M 10-Q · filed 2021-08-11 | $21.67M 10-Q · filed 2021-08-11 | $31.86M derived: sum of 3 quarters · filed 2021-08-11 | $40.44M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $10.68M 10-Q · filed 2021-05-11 | $20.87M derived: sum of 2 quarters · filed 2021-05-11 | $29.45M derived: sum of 3 quarters · filed 2021-05-11 | $37.72M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $10.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $18.77M derived: sum of 2 quarters · filed 2021-03-11 | $27.04M derived: sum of 3 quarters · filed 2021-03-11 | $34.91M 10-K · filed 2021-03-11 |
| 2019-09-30 | $8.58M 10-Q · filed 2020-11-16 | $16.85M derived: sum of 2 quarters · filed 2020-11-16 | $24.72M 10-Q · filed 2020-11-16 | $33.10M derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $8.27M 10-Q · filed 2020-08-13 | $16.14M 10-Q · filed 2020-08-13 | $24.52M derived: sum of 3 quarters · filed 2020-08-13 | $33.70M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $7.87M 10-Q · filed 2020-05-14 | $16.25M derived: sum of 2 quarters · filed 2020-05-14 | $25.43M derived: sum of 3 quarters · filed 2020-05-14 | |
| 2018-12-31 | $8.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $17.56M derived: sum of 2 quarters · filed 2020-03-30 | $31.77M 10-K · filed 2020-03-30 | |
| 2018-09-30 | $9.18M 10-Q · filed 2019-12-11 | $23.39M 10-Q · filed 2019-12-11 |